鼻内接种流感/新冠双价单复制病毒载体疫苗保护仓鼠免受SARS-CoV-2攻击
研究在仓鼠攻击模型中比较鼻内M2SR SARS-CoV-2单复制流感病毒载体疫苗与肌内注射佐剂灭活全病毒疫苗对Wuhan SARS-CoV-2的保护效果。鼻内M2SR疫苗保护效果优于肌内注射佐剂灭活全病毒疫苗,并诱导针对Wuhan和Omicron的中和血清抗体及交叉反应性黏膜抗体,同时诱导与H3N2 M2SR流感疫苗相似的流感血清HAI和黏膜抗体应答。鼻内双价流感/新冠M2SR疫苗有潜力同时提供对流感和COVID的保护。
要点
- 鼻内M2SR SARS-CoV-2疫苗对Wuhan SARS-CoV-2攻击的保护效果优于肌内注射佐剂灭活全病毒疫苗。
- M2SR SARS-CoV-2诱导针对Wuhan和Omicron SARS-CoV-2的中和血清抗体及交叉反应性黏膜抗体。
- M2SR SARS-CoV-2诱导的流感血清HAI和黏膜抗体应答与H3N2 M2SR流感疫苗相似。
核心结论
- 鼻内双价流感/新冠M2SR SARS-CoV-2疫苗有潜力同时提供对流感和COVID的保护。
研究设计与样本
- 在仓鼠攻击模型中评估鼻内接种M2SR SARS-CoV-2(编码SARS-CoV-2受体结合域的M2缺失单复制流感病毒载体)对Wuhan SARS-CoV-2攻击的保护效果。
- 同时评估肌内注射佐剂灭活SARS-CoV-2全病毒疫苗。
主要发现
- 鼻内M2SR SARS-CoV-2在提供针对SARS-CoV-2攻击的保护方面比肌内注射佐剂灭活全病毒疫苗更有效。
- M2SR SARS-CoV-2诱导针对Wuhan和Omicron SARS-CoV-2病毒的中和血清抗体以及交叉反应性黏膜抗体。
- M2SR SARS-CoV-2诱导的针对流感的血清HAI和黏膜抗体应答与H3N2 M2SR流感疫苗相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has highlighted the need for mucosal vaccines as breakthrough infections, short-lived immune responses and emergence of new variants have challenged the efficacy provided by the first generation of vaccines against SARS-CoV-2 viruses. M2SR SARS-CoV-2, an M2-deleted single-replication influenza virus vector modified to encode the SARS-CoV-2 receptor binding domain, was evaluated following intranasal delivery in a hamster challenge model for protection against Wuhan SARS-CoV-2. An adjuvanted inactivated SARS-CoV-2 whole virus vaccine administered intramuscularly was also evaluated. The intranasal M2SR SARS-CoV-2 was more effective than the intramuscular adjuvanted inactivated whole virus vaccine in providing protection against SARS-CoV-2 challenge. M2SR SARS-CoV-2 elicited neutralizing serum antibodies against Wuhan and Omicron SARS-CoV-2 viruses in addition to cross-reactive mucosal antibodies. Furthermore, M2SR SARS-CoV-2 generated serum HAI and mucosal antibody responses against influenza similar to an H3N2 M2SR influenza vaccine. The intranasal dual influenza/COVID M2SR SARS-CoV-2 vaccine has the potential to provide protection against both influenza and COVID.
引用
- Hill-Batorski L, Bowen R, Bielefeldt-Ohmann H, et al. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge. Vaccine. 2024. PMID: 38508930. doi:10.1016/j.vaccine.2024.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。